Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients

This study has been terminated.
(The study needed to be terminated due to new knowledge about cancer vaccines. A new protocol with an expected more efficient vaccine is currently being written.)
Sponsor:
Information provided by:
Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT01334047
First received: March 30, 2011
Last updated: August 22, 2014
Last verified: August 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: April 2022
  Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)